Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt small index

Graves Disease: early-phase trial registry

9 of 12 indexed Graves Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 9 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Graves Disease: 12 US clinical trials tracked, 9 recruiting.

Graves Disease is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Immunovant Sciences, running 2 of these trials.

Enrollment posture brief

Registry condition graves-disease

OPEN 9 | RECR 75% | LATE 1 | EARLY 7 | RANK #1429 | SPON 2

Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)

Graves Disease (this)75%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Graves Disease

Graves Disease lists 9 open slots (75% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Graves Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Graves Disease is recruiting above its size-band peers.

    9 of 12 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Graves Disease research.

    Immunovant Sciences accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Graves Disease enrolment sits around 93 participants.

    Median target enrolment is 93 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.

  4. Graves Disease research is mostly interventional.

    10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 25Phase 41

Open and recent trials

12 total, page 1 of 1

RECRUITING 2,500 participants

Natural History of Thyroid Function Disorders

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00001159

RECRUITING Phase 2 240 participants

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Immunovant Sciences

NCT06727604

RECRUITING Phase 2 210 participants

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Immunovant Sciences

NCT07018323

RECRUITING Phase 1 100 participants

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

Merida Biosciences

NCT07305818

RECRUITING 100 participants

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

Walter Reed National Military Medical Center

NCT06275373

RECRUITING Phase 4 76 participants

Preoperative Corticosteroids in Autoimmune Thyroid Disease

Indiana University

NCT05435547

RECRUITING Phase 2 30 participants

Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

Northwell Health

NCT07369063

RECRUITING Phase 1 15 participants

Study of BHV-1300 in Graves' Disease

Biohaven Therapeutics

NCT06980649

RECRUITING NA 10 participants

Personalized Treatment in Thyroid Disorders

Johns Hopkins University

NCT03517579

COMPLETED NA 93 participants

Shared Decision Making in Graves Disease - Graves Disease (GD) Choice

Mayo Clinic

NCT02107794

COMPLETED Phase 2 19 participants

Radioactive Iodide Therapy for Pediatric Graves' Disease

University of Florida

NCT01269749

COMPLETED Phase 2 15 participants

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Novartis Pharmaceuticals

NCT02713256

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 4 1

Named interventions

Most-linked intervention names on Graves Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
IMVT-1402 Drug
2 trials
ATD Group Drug
1 trials
RAI treatment Radiation
1 trials
CFZ533 Drug
1 trials
Teprotumumab Injection [Tepezza] Drug
1 trials
Cervical Collar Therapy Indicator (COTI) Device
1 trials
BHV-1300 Drug
1 trials

US sites by state

Facility locations filed on Graves Disease trials. A trial with sites in several states counts in each.

Florida 5 trials
Texas 3 trials
Maryland 3 trials
California 3 trials
Arizona 3 trials
New York 2 trials
Minnesota 2 trials
Georgia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Graves Disease page

12 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Graves Disease condition card totals 12 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.